Table 2.
Risk factors for shorter survival among participants with incident ischemic stroke
Unadjusted* | Fully Adjusted† | |||||||||
---|---|---|---|---|---|---|---|---|---|---|
| ||||||||||
n‡ | HR | 95% CI | p-value | Int. § | n‡ | HR | 95% CI | p-value | Int. § | |
Pre-Frail | ||||||||||
<80 years | 300 | 1.48 | 1.13, 1.94 | 0.003 | 0.20 | 294 | 1.64 | 1.23, 2.18 | 0.001 | 0.04 |
≥80 years | 232 | 1.11 | 0.78, 1.57 | 0.57 | 221 | 0.99 | 0.68, 1.46 | 0.96 | ||
Frail | ||||||||||
<80 years | 300 | 2.08 | 1.38, 3.13 | <0.001 | 0.05 | 294 | 2.03 | 1.31, 3.16 | 0.002 | 0.06 |
≥80 years | 232 | 1.18 | 0.79, 1.76 | 0.43 | 221 | 1.13 | 0.71, 1.80 | 0.61 | ||
CRP || | 616 | 1.05 | 0.99, 1.10 | 0.11 | 606 | 1.05 | 0.99, 1.12 | 0.08 | ||
IL-6 || | ||||||||||
<80 years | 294 | 1.47 | 1.30, 1.67 | <0.001 | 0.007 | 292 | 1.41 | 1.23, 1.62 | <0.001 | 0.03 |
≥80 years | 291 | 1.13 | 0.97, 1.30 | 0.12 | 285 | 1.12 | 0.95, 1.31 | 0.17 | ||
Cystatin C || | 578 | 2.24 | 1.81, 2.77 | <0.001 | 568 | 1.97 | 1.55, 2.50 | <0.001 | ||
Systolic Blood Pressure# | 637 | 1.01 | 0.97, 1.04 | 0.62 | 622 | 1.02 | 0.98, 1.05 | 0.39 | ||
Diastolic Blood Pressure# | 637 | 0.96 | 0.90, 1.03 | 0.23 | 622 | 0.99 | 0.92, 1.06 | 0.79 | ||
Total Cholesterol¶ | ||||||||||
<80 years | 312 | 0.99 | 0.96, 1.03 | 0.70 | 0.02 | 309 | 1.02 | 0.98, 1.05 | 0.36 | 0.10 |
≥80 years | 307 | 0.94 | 0.92, 0.97 | <0.001 | 300 | 0.98 | 0.95, 1.00 | 0.16 |
Adjusted for time between risk factor assessment and stroke
Adjusted for time between risk factor assessment and stroke, ischemic stroke subtype, stroke location, race, sex, education attainment, smoking status, alcohol consumption, living alone status, atrial fibrillation, coronary heart disease, congestive heart failure, diabetes, depression (CES-D>12), low cognitive function (3MSE<80), BMI, anti-coagulant use, and anti-hypertensive medication use
n in each analysis
p-value for interactions
per doubling in concentration
per 10 mm Hg
per 10 mg/dL